JP Morgan Chase’s BridgeBio Pharma BBIO Stock Holding History

JP Morgan Chase’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$153K	Sell	2,200 -14,000	-86%	-$1.01M	﹤0.01%	5613
2025 Q4	$1.24M	Sell	16,200 -6,500	-29%	-$427K	﹤0.01%	4452
2025 Q3	$1.18M	Sell	22,700 -17,300	-43%	-$844K	﹤0.01%	4468
2025 Q2	$1.73M	Hold	40,000	–	–	﹤0.01%	4022
2025 Q1	$1.38M	Buy	40,000 +37,300	+1,381%	+$1.26M	﹤0.01%	4127
2024 Q4	$74.1K	Hold	2,700	–	–	﹤0.01%	5868
2024 Q3	$68.7K	Buy	+2,700	New	+$70.9K	﹤0.01%	5865
2023 Q3	–	Sell	-23,700	Closed	-$408K	–	7460
2023 Q2	$408K	Buy	23,700 +15,700	+196%	+$236K	﹤0.01%	4620
2023 Q1	$133K	Buy	+8,000	New	+$93.3K	﹤0.01%	5293
2022 Q1	–	Sell	-77,400	Closed	-$1.29M	–	6588
2021 Q4	$1.29M	Buy	+77,400	New	+$3.27M	﹤0.01%	4201

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's BBIO Position: Q1 2026 in Review

JP Morgan Chase increased its BridgeBio Pharma (BBIO) stake by 53% in Q1 2026, buying an estimated $32.9M and bringing the position to 1,312,259 shares worth $91M. The position accounts for 0.01% of the portfolio, ranked #1041.

JP Morgan Chase first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. The position peaked at $98.3M in Q2 2021. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

JP Morgan Chase held 1,312,259 shares of BridgeBio Pharma worth $91M as of Q1 2026.
JP Morgan Chase bought 453,291 BridgeBio Pharma shares in Q1 2026, an estimated $32.9M.
BridgeBio Pharma made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1041 holding.
JP Morgan Chase first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
JP Morgan Chase's BridgeBio Pharma position peaked at $98.3M in Q2 2021.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.